Use your antibodies-online credentials, if available.
Il n’y a pas de produits dans votre liste de comparaison.
Votre panier est vide.
Afficher toutes les espèces
Afficher tous les synonymes
Sélectionnez vos espèces et l'application
anti-Rat (Rattus) MSH3 Anticorps:
anti-Human MSH3 Anticorps:
anti-Mouse (Murine) MSH3 Anticorps:
Vous arrivez à notre recherche pré-filtrée.
Human Polyclonal MSH3 Primary Antibody pour ICC, IF - ABIN4335850
Amaral-Silva, Sánchez-Romero, Wagner, Martins, Pontes, Fregnani, Soares, Almeida, Rocha, Santos-Silva, Fonseca, Vargas: Prognostic significance of hMSH2, hMSH3, and hMSH6 expression in ameloblastoma. dans Oral surgery, oral medicine, oral pathology and oral radiology 2017
The role of MSH3 in 11 Lynch Syndrome patients with truncating MSH6 (Montrer MSH6 Anticorps) germline variants and an unexplained MSH2 (Montrer MSH2 Anticorps) protein loss.Heterozygous MSH3 defects alone do not seem to induce a Lynch Syndrome phenotype
MSH3 was frequently inactivated by promoter methylation and its mRNA and protein expression correlated with the primary tumor stage in nasopharyngeal carcinoma.
Msh3-/- cells are severely defective for CTG*CAG repeat (Montrer CELF3 Anticorps) expansions but show full activity on contractions. Msh3 overexpression led to high expansion activity and elevated levels of MutSbeta complex, indicating that MutSbeta abundance drives expansions. Expression of 2 Msh3 polymorphic variants at normal levels showed no detectable change in expansions. These polymorphisms primarily affect Msh3 protein stability, not ac...
Findings indicate that carriers of the MSH5 (Montrer MSH5 Anticorps) rs707939 T allele, the MSH2 (Montrer MSH2 Anticorps) rs6544991 C allele, the MSH3 rs6151627 and rs6151670 G alleles, and the MSH3 rs7709909 T allele have poor toxicity tolerance to platinum-based chemotherapy in non-small cell lung cancer patients.
MSH3 is probably a modifier of disease progression in Huntington's disease.
data suggest that MSH3 mutations represent an additional recessive subtype of colorectal adenomatous polyposis
Three polymorphisms in MSH3 were associated with variation in somatic instability in myotonic dystrophy type 1.
Our meta-analysis results demonstrated that MSH3 rs26279 G > A polymorphism is associated with an increased risk of overall cancer, especially for the colorectal cancer and breast cancer.
The mismatch-binding protein MutS beta, a heterodimer of MSH2 and MSH3, activates ATR in response to DNA double-strand breaks.
Data show that single nucleotide polymorphisms in MutS homolog 3 (MSH3) had an impact on the chemotherapy response and prognosis of advanced non-small cell lung cancer (NCSLC) patients who were treated with platinum-based chemotherapy.
Mutation of a critical residue within the ATPase (Montrer DNAH8 Anticorps) domain of Msh3 did not preclude mismatch repair at the genomic sequences tested.
MSH2 (Montrer MSH2 Anticorps)-MSH3 suppresses chromosomal instability and modulates the tumor spectrum in p53 (Montrer TP53 Anticorps)-deficient tumorigenesis.
naturally occurring MSH3 protein polymorphisms are modifiers of CAG repeat (Montrer CELF3 Anticorps) instability, likely through variable MSH3 protein stability
Enhanced occupancy of Msh2 (Montrer MSH2 Anticorps) and Msh3 proteins downstream of the FXN (Montrer FXN Anticorps) expanded GAA (Montrer GAA Anticorps) repeat, suggesting a model in which Msh2 (Montrer MSH2 Anticorps)/3 dimers are recruited to this region to repair mismatches.
Stress treatment of mouse cells with ethanol or hydrogen peroxide caused the re-distribution of MSH3 into nuclear bodies containing the proliferating cell nuclear antigen (PCNA (Montrer PCNA Anticorps)), a known binding partner of MutSbeta.
A (CTG)84 repeat was stable even in Msh3-deficient mice.
Data suggest that MutS homologues Msh2 (Montrer MSH2 Anticorps), Msh3, and Msh6 (Montrer MSH6 Anticorps) play overlapping and distinct roles during antibody diversification processes.
Data suggest that activation-induced cytidine deaminase (Montrer AICDA Anticorps) has limited entry points into V and S regions in vivo, and subsequent mutation requires Msh2 (Montrer MSH2 Anticorps)-Msh6 (Montrer MSH6 Anticorps), but not Msh3, and DNA polymerase (Montrer POLB Anticorps).
Frequencies and patterns in DNA mismatch repair in the context of mice deficient for Msh3.
The protein encoded by this gene forms a heterodimer with MSH2 to form MutS beta, part of the post-replicative DNA mismatch repair system. MutS beta initiates mismatch repair by binding to a mismatch and then forming a complex with MutL alpha heterodimer. This gene contains a polymorphic 9 bp tandem repeat sequence in the first exon. The repeat is present 6 times in the reference genome sequence and 3-7 repeats have been reported. Defects in this gene are a cause of susceptibility to endometrial cancer.
DNA mismatch repair protein Msh3
, DNA mismatch repair protein MSH3
, hypothetical protein
, divergent upstream protein
, mismatch repair protein 1
, protein repair-1
, protein repair-3